Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADMP agreed 68 Mill $$ Mkt Cap is insanely cheap especially considering ADMP pipeline & multiple Billion dollar avenue drugs. Their 3M partnership on 8 Bill $$$ Advair Mkt where NO current generic is on the Mkt makes this tiny Biotech worth many multiples of 68 MILLION $$$$ nuts..
sorry ADMP the symbol
$7's breaking out DD tiny Biotech co. 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
$7's breaking out ADMP tiny Biotech co. 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
ADMP DD post tiny Biotech co. 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
ADMP nice Vol bars & price action
ADMP tiny 63 mill $$ Mkt Cap Biotech 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
MGT form 4 filing first insider buy since 2012 near 52 week low as been basing here since Dec & tax loss selling .... multiple catalysts near term for MGT ...N.J. online gambling license s/b granted this month & Feb marksman hearing paperwork for patent case starts
NSYS nice move today on above avg Vol tiny float & good fundies
ADMP DD post. ADMP tiny Biotech co. 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition,enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
ADMP 65 mill $$ market Cap Bio & 3M partnership on generic Advair inhaler.. huge 8 Bill $ market & FDA just recently relaxed guidelines on generic advair link read last paragraph carefully as TEVA gave up already & ADMP hooked up with 3M top tier co. with long history inventing inhaler products... Certainly Under the Radar of just about everyone right now.
http://www.rxobserver.com/?p=1568
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
NSYS with 2.7 mill shares & 1.2 mill share float as founder Myron Kunin owns over 51% & insiders total over 53% of shares. NSYS is profitable year after year & finally seeing some nice growth again as last Qtr sales up 7% & CEO remarked how business picking up evidenced by backlog jump from 16 mill $$$ to 18.5 Million. Pipeline of biz also positive according to CEO remarks in the Aerospace & Industrial side. So besides being a well run profitable co. a Catalyst for some maybe in the fact NSYS has grown their shareholder net worth year after year as well.
Net Tangible Assets after Debt = 21.7 million dollars ( NO goodwill or Intangible assets on balance sheet) that 21.7 million dollars = $7.85 a share .NSYS also has a 3D angle which sparked interest & volume recently link
http://www.intercon-1.com/CoreCompetencies/mechanical.aspx
http://www.nortechsys.com/
while imo the 3D is a weak one NSYS has a small one none the less.
ADMP & 3M with new advair generic & FDA relaxed generic guidelines making it easier & faster to get it to market link
http://www.bloomberg.com/news/2013-09-10/glaxo-falls-most-in-20-months-on-fda-generic-rules.html
ADMP 56 mill $$ market Cap Bio & 3M partnership on generic Advair inhaler.. huge 8 Bill $ market & FDA just recently relaxed guidelines on generic advair link read last paragraph carefully as TEVA gave up already & ADMP hooked up with 3M top tier co. with long history inventing inhaler products... Certainly Under the Radar of just about everyone right now.
http://www.rxobserver.com/?p=1568
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
60 Mill $$ Mkt Cap with 20 Mill in Cash do DD 3M as partner
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://seekingalpha.com/instablog/12510571-james-w-burke/2483121-is-a-cancer-vaccine-closer-than-we-think?source=kizur_seekingalpha
ADMP Naz uplist today 3M partnering product & nice pipeline do some DD this is a good read
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
ADMP new Nasdaq uplist Bio play did reverse & offering also has just under 10 million shares outstanding & a float of approx. 6 million shares as very insider owned. Bought exclusive rights to 3M inhaler tech. nice read here on ADMP one to watch in 2014 imo....
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
AMBI like SRPT tanked on FDA news that they both have to do a phase 3 trial SRPT up $7 a share from tank AMBI s/b back to $10's imo
AMBI way overdone big bounce play as Co was always planning to do phase 3 trial all along... FDA approval off phase 2 results were always a big long shot & AMBI management clearly stated that many times ... Citibank out defending AMBI
Happy Turkey week NSYS microfloat alert wanted to give some DD on a potential holiday play winner link
http://www.thelion.com/bin/forum.cgi?tf=wall_street_pit&msg=2429966&cmd=r&t=
True typically microfloats NSYS a Superman pick s/b added to watchlist imo ran from $6 to $9.60 on small 3D angle that NSYS has & earnings that were good
TNXP microfloat Bio under thre radar came up on increased vol scan the last few sessions & after OXBT blowup picked up a few shares
APPY Newswire.. CASTLE ROCK, Colo., Sept. 26, 2013 /PRNewswire/ -- Venaxis, Inc. (APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced that the external Data and Safety Monitoring Board (DSMB) created as part of the Company's pivotal clinical trial for the APPY1 Test has recommended continuation of the pivotal clinical trial, based upon completion of the second and final futility analysis included in the clinical trial design.
The futility analysis, which consisted of an independent review of the validity, integrity, and clinical and scientific relevance of the ongoing study, was performed on the first 1,061 patients to complete the study. On July 15, 2013, Venaxis® announced that the study would continue following a previous futility analysis performed on the first 579 patients to complete the study. The pivotal study will enroll a total of 2,000 evaluable patients, of which approximately 1,300 have been enrolled to date. Venaxis is on track to complete enrollment as guided by the end of 2013.
Steve Lundy, President and CEO of Venaxis, stated, "Since initiating patient enrollment in our pivotal study earlier this year, we have focused significant effort on meeting our recruitment goals. We've worked closely with our clinical sites and enhanced our approach along the way, and through those efforts we have been successful in ramping our enrollment rates efficiently. Further encouraged by the DSMB's final recommendation to complete the trial as designed, we continue to anticipate enrollment completion by the end of 2013, and subject to the clinical trial results, file for FDA clearance in the first quarter 2014."
APPY nice 80% winner & New short interest out lmao up again to 1.85 million underwater money losing shorts....
APPY s/b gapper tomorrow after long basing action $1.40's & catalysts coming soon.... plus doesn't hurt that almost 2/3rd's APPY market cap is in CASH !!!!!
ALXA nice climb since TEVA news $4.666 HOD from $4.30 alert
APPY $1.40 support been huge during basing process will lead to nice breakout soon imo.... especially with catalysts near term....
APPY Sheff did you re enter $1.40 ? looking good $1.48 thanks ....GLTA & make $$$$$$$$$$$$$$$$$
ALXA just out... Teva reports top-line results from Phase III study of NUVIGIL
Teva Pharmaceutical announced top-line results of its final Phase III clinical study for armodafinil as adjunct therapy in adults with major depression associated with bipolar I disorder. The study reached statistical significance in several important secondary endpoints, such as responder rate and remission. However, it did not reach its primary endpoint --to determine whether armodafinil treatment is more effective than placebo as adjunct therapy to mood stabilizers and/or atypical antipsychotics. This study was the third of three, Phase III studies, all of which demonstrated improvements in patient response. However, based on an evaluation of the totality of results, Teva will not proceed with regulatory filings for armodafinil for the treatment of major depression associated with bipolar I disorder. There is no material impact to the company, Teva said.
ALXA good news out ? TEVA Bipolar mood disorder drug just failed & TEVA partnered with ALXA on their FDA approved bipolar mood disorder drug ?
O.T. CIMT recent runner on 3D angle did small offering today 900K & being received very well & moving back up considering it was mid $7's this week....
http://seekingalpha.com/article/1657512-3-d-stocks-surge-again-one-that-is-undervalued-and-could-see-30?source=yahoo
ALXA picked up few in $4.20's oversold & nice partners TEVA & high amount of cash in the bank ...product launch later this year by TEVA
APPY added back trading shares $1.40 at support been perfect add area
AUXL has their PDUFA date pushed out from Sept 6th to Dec 6th...link
http://finance.yahoo.com/news/auxilium-receives-notification-xiaflex-pdufa-100000188.html
APPY nice article Bob the risk/reward is heavily slanted in longs favor being a test & not a drug trial & has already had a trial with 97% success rate. Coupled with a 30 million dollar market cap & 20 million of that in cash. Throw in the Institutions discovering APPY seems like smart money to me. GLTA & make $$$$$$$$$$$$$$$$$$$$$$$$
APPY also Institutional ownership doubled this Qtr over last & again all one way all buys & no sells. BTW on Naz.com Perkins has not updated but he did file a 13G & tripled his holdings bring tutes to almost 4 million shares. As of Dec 31 2012 APPY had approx. 400K. With 2/3rds the Market Cap in cash & near term catalysts makes APPY a very strong risk/reward play & following the big boy buys.... GLTA & make $$$$$$$$$$$$$$$$$
Stop thinking lol... 10Q has been out since 8-7 last Wed ....
Coe Capital a new Institutional owner listed bought 225,000 shares ... most Institutional holdings will be updated by Thursday this week.... remember 1.6 million shares were bought in 1st Qtr with 40K in sells so far that crazy one way trend continues...